Frequency Therapeutics (FREQ) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month target prices for Frequency Therapeutics' stock. Their FREQ share price forecasts range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 1,561.0% from the stock's current price.
View analysts price targets for FREQ or view top-rated stocks among Wall Street analysts.

Frequency Therapeutics' stock was trading at $3.85 at the start of the year. Since then, FREQ stock has decreased by 90.1% and is now trading at $0.3813.
View the best growth stocks for 2023 here.

Frequency Therapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 533,500 shares, a drop of 39.1% from the August 15th total of 876,500 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 0.3 days. Approximately 1.6% of the company's stock are short sold.
View Frequency Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our FREQ earnings forecast.

Frequency Therapeutics, Inc. (NASDAQ:FREQ) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14.

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

(FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ."

Frequency Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.42%), Renaissance Technologies LLC (1.14%), GTS Securities LLC (0.61%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Carl Lebel, Christopher R Loose, David L Lucchino, Joel S Marcus, Peter P Pfreundschuh, Quentin Mccubbin and Richard J Mitrano.
View institutional ownership trends.

Shares of FREQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FREQ stock can currently be purchased for approximately $0.38.

Frequency Therapeutics (NASDAQ:FREQ) has a market capitalization of $13.93 million and generates $14.07 million in revenue each year. The company earns $-81,580,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The official website for the company is www.frequencytx.com. The company can be reached via phone at 781-315-4600 or via email at investorrelations@frequencytx.com.